Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Esophageal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Fluorouracil

Cisplatin

Tubulin Modulators

Antimitotic Agents

preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks

preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week

preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks)

Paclitaxel, Cisplatin Plus 5-FU (TCF)

preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week)

radiochemotherapy

Yi Ba, MD,PHD

Yi Ba, MD.PHD

likun Zhou, MD

Hongli Li, MD.PHD

Ting Deng, MD.

Xia Wang, MD

Ming Bai, MD

Rui Liu, MD.PHD

Shaohua Ge, MD.PHD

Le Zhang, MD

Tao Ning, MD.PHD

Zhentao Yu, MD.PHD

This is a Phase III clinical trail which Comparing Paclitaxel, Cisplatin Plus 5-FU (TCF) Versus Radiotherapy with Paclitaxel Plus Cisplatin (TC-RT) as Preoperative Therapy for Locally Advanced Esophageal Squamous Cancer. The Preoperative chemoradiotherapy with radical surgery is the standard treatment in China. But, many patients do not receive this treatment for many other reasons. Most of them refused or abandon radiotherapy because of the Intolerable adverse effects of radiotherapy, so we have launched a randomized controlled trial to confirm the non-inferiority of TCF over chemoradiotherapy with TC (TC-RT) as preoperative therapy for locally advanced esophageal squamous cancer in overall survival.

Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC

A Phase III Trial Comparing Paclitaxel, Cisplatin Plus 5-FU (TCF) Versus Radiotherapy With Paclitaxel Plus Cisplatin (TC-RT) as Preoperative Therapy for Locally Advanced Esophageal Squamous Cancer

All participants with treatment-related adverse events as assessed by CTCAE v4.0

Shanghai Chest Hospital

Henan Cancer Hospital

The First Affiliated Hospital with Nanjing Medical University

First Affiliated Hospital of Chongqing Medical University

The First Affiliated Hospital of Anhui Medical University

Tianjin Medical University Cancer Institute and Hospital

Cetuximab

Oxaliplatin

Antineoplastic Agents, Immunological

radiochemotherapy,combination Cetuximab-FOLFOX

objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX

Gérard LLEDO, MD

This phase II trial is studying the effects of oxaliplatin, leucovorin and fluorouracil-when given together with Cetuximab and radiation therapy and radiation therapy to see how they work in treating patients with stage III esophageal cancer.

Cetuximab is a monoclonal antibody which can block the ability of tumor cells to grow and spread Cetuximab may also make tumor cells more sensitive to radiation therapy. Drug used in chemotherapy such as oxaliplatin leucovorin and Fluorouracil work in different way to stop the growth of tumor cells either by killing the cells or by stopping them form dividing. Radiation therapy uses high energy X rays to kill tumor cells. Giving cetuximab could improve the efficacy of chemotherapy and radiation therapy and may make the tumor smaller This phase II trial is studying the effects of oxaliplatin, leucovorin and fluorouracil-when given together with Cetuximab and radiation therapy and radiation therapy to see how they work in treating patients with stage III esophageal cancer.

FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer

Phase II Trial of FOLFOX in Combination With Cetuximab and Concomitant Radiotherapy in the Treatment of Esophageal Cancer Stage III

GERCOR - Multidisciplinary Oncology Cooperative Group

Assistance Publique - Hôpitaux de Paris

Isabelle BRINDEL

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC	NCT03366883	Esophageal Canc... Esophageal Canc...	Paclitaxel, Cis... radiochemothera...	20 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer	NCT00578201	Esophageal Canc...	radiochemothera...	18 Years - 80 Years	Assistance Publique - Hôpitaux de Paris
FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer	NCT00578201	Esophageal Canc...	radiochemothera...	18 Years - 80 Years	Assistance Publique - Hôpitaux de Paris
FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer	NCT00578201	Esophageal Canc...	radiochemothera...	18 Years - 80 Years	Assistance Publique - Hôpitaux de Paris

Spots Global Cancer Trial Database for esophageal cancer stage iii